Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergi... ( LONDON Oct. 29 /- Morria Biopharm...)

HOME >> MEDICINE >> NEWS

Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis

Date:10/29/2008

LONDON, Oct. 29 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs, announced today the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort(R) as the steroid comparator arm.

A secondary efficacy endpoint of this study was the effect of MRX-4 on inflammatory mediators/markers in the nasal lavage of selected patients following allergen stimulus. The patients were pre-treated by either a placebo or MRX-4 for 7 days twice per day (b.i.d.) beforehand.

MRX-4 demonstrates an overall trend of reducing the levels of five inflammatory mediators: IL-5 (interleukin-5), IL-13, TNF-alpha (Tumor Necrosis Factor alpha), MCP-1 (Monocyte Chemoattractant Protein-1) and Eotoxin. These mediators have been shown to play an important role in various inflammatory diseases such as allergic rhinitis, asthma, skin and intestinal inflammation and arthritis. All have previously been shown to be modulated by MRX-4 in vitro and in vivo in pre-clinical models. This is the first time that such modulation has been observed in patients.

In addition, the levels of eosinophils were tested in the nasal lavage. Eosinophils are white blood cells that play a key role in the allergic response. MRX-4 reduced the levels of these cells compared to placebo-treated patients.

"We are pleased by the wide range of divergent inflammatory mediators that we are modulating, several of which have been extensively covered in the scientific literature recently. Mediators, such as IL-5, IL-13 and TNF-alpha, are currently targets of research and development in the pharmaceutical field for treating respiratory inflammatory diseases, and MRX-4 modulates them in these patients," said Yuval Cohen, Pr
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
3. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
5. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)

Post Your Comments:

Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergi...( LONDON Oct. 29 /- Morria Biopharm...),Health